moderna vaccine sold brand name spikevax vaccine developed american company moderna united states national institute allergy infectious diseases niaid biomedical advanced research development authority barda depending jurisdiction authorized use people aged six twelve years eighteen years older provides protection caused infection designed administered two three ml doses given intramuscular injection interval least days mrna vaccine composed nucleosidemodified mrna modrna encoding spike protein encapsulated lipid authorized use level many august september bivalent versions vaccine moderna vaccine bivalent containing elasomeranelasomeran spikevax bivalent authorized use booster doses individuals aged years age older united european united second component version bivalent vaccine used united states based omicron second component bivalent vaccine version used countries based omicron moderna vaccine used provide protection infection virus order prevent vaccine given intramuscular injection deltoid muscle initial course consists two world health organization recommends interval eight weeks third fourth fifth dose added evidence vaccine efficacy starts two weeks first high efficacy achieved full immunization two weeks second dose evaluated end vaccine study led emergency authorization us eleven cases vaccine group people versus cases placebo group moreover zero cases severe vaccine group versus eleven placebo efficacy described borderline respiratory virus vaccine similar efficacy efficacy estimates similar across age groups sexes racial ethnic groups participants medical comorbidities associated high risk severe individuals aged older studied studies underway gauge efficacy safety children aged kidcove study conducted us centers disease control prevention cdc december march nearly thousand health care personnel first responders essential frontline workers concluded realworld conditions mrna vaccine effectiveness full immunization days second dose infections regardless symptoms vaccine effectiveness partial immunization days first dose second dose duration protection provided vaccine unknown april twoyear followup study underway determine preliminary results phase iii trial indicate vaccine efficacy durable remaining six months second vaccine generally considered effective estimate lower limit confidence effectiveness generally expected slowly decrease august results study suggested effectiveness infection decreased delta variant became predominant us may due unmeasured residual confounding related decline vaccine effectiveness limited data available safety moderna vaccine initial study excluded pregnant women discontinued vaccination upon positive pregnancy studies animals found safety concerns clinical trials underway evaluate safety efficacy vaccines pregnant realworld observations cdc vsafe tracking program uncovered unusual numbers adverse events outcomes based results preliminary study us cdc recommends pregnant women get vaccinated world health organization stated safety data supported favorable safety profile vaccines ae adverse event profile suggest specific safety common adverse events pain injection site fatigue headache myalgia muscle pain arthralgia joint us centers disease control prevention cdc reported anaphylaxis severe allergic reaction cases per million doses administered recommended observation period delayed cutaneous reactions injection sites resulting rashlike erythemas also observed rare cases considered serious contraindications subsequent incidence rate local adverse erythema cases redness may extend size mm june us cdc confirmed myocarditis pericarditis occurs every million young people mostly male age received moderna affected individuals recover quickly adequate treatment additional side effects include extensive swelling vaccinated modernas technology uses nucleosidemodified messenger rna modrna compound codenamed drug delivery system uses pegylated lipid nanoparticle drug delivery lnp compound inside human cell mrna links cells endoplasmic reticulum encoded trigger cell making specific protein using cells normal manufacturing process vaccine encodes version spike protein modification called protein includes two stabilizing mutations original amino acids replaced prolines developed researchers university texas austin national institute allergy infectious diseases vaccine research protein expelled cell eventually detected immune system begins generating efficacious antibodies vaccine contains following active ingredient mrna sequence containing total nucleotides encodes fulllength spike two mutations designed stabilize prefusion conformation sequence optimized putative sequence vaccine published forum professional virologists obtained direct sequencing residual vaccine material used vaccine mrna dissolved aqueous buffer containing tromethamine tromethamine hydrochloride sodium acetate mrna encapsulated lipid nanoparticles stabilize mrna facilitate entry nanoparticles manufactured following lipids moderna relying extensively contract manufacturing organizations scale vaccine manufacturing process first step dna plasmids used template synthesis handled contractor called aldevron based fargo north remainder process moderna contracted lonza group manufacture vaccine facilities portsmouth new hampshire united states visp switzerland purchased necessary lipid excipients besides cmos moderna also manufactures vaccine production facility norwood another manufacturing site vaccines market outside us since end geleen netherlands produced manufacturing partner earlier lonza produce vaccine eu uk canada site switzerland cut projected deliveries uk canada earlier due production tasks filling packaging vials fill finish moderna entered contracts catalent united states laboratorios farmacéuticos rovi april moderna expanded agreement catalent increase manufacturing output latters plant bloomington indiana expansion allow catalent manufacture vials per minute fill additional million vials per later month moderna announced plans spend billions dollars boost production vaccines potentially tripling output claiming well would make less million doses increase production part attributed improvements made company manufacturing moderna news followed preliminary results pfizerbiontech vaccine candidate moderna demonstrating similar efficacy requiring storage temperature standard medical refrigerator thirty days four months whereas pfizerbiontech candidate requires ultracold freezer storage lowincome countries usually cold chain capacity standard refrigerator storage ultracold freezer february restrictions pfizer vaccine relaxed us food drug administration fda updated emergency use authorization eua permit undiluted frozen vials vaccine transported stored two weeks moderna vaccine stored temperature november nature reported possible differences lnp formulations mrna secondary structures could account thermostability differences moderna biontech many experts suspect vaccine products ultimately prove similar storage requirements shelf lives various temperature january moderna announced development rna vaccine codenamed induce immunity moderna received million biomedical advanced research development authority barda office us department health human services barda funded cost bringing vaccine fda united states government provided billion total funding moderna vaccine private donors also made contributions vaccines development dolly parton research fund contributed march phase human trial began partnership us national institute allergy infectious april us biomedical advanced research development authority barda allocated million modernas vaccine plans phase ii dosing efficacy trial begin may approved us food drug administration moderna signed partnership swiss vaccine manufacturer lonza supply million doses per may moderna began phase iia clinical trial recruiting six hundred adult participants assess safety differences antibody response two doses candidate vaccine study expected complete july moderna scientists published preliminary results phase dose escalation clinical trial showing dosedependent induction neutralizing antibodies early days postinjection mild moderate adverse reactions fever fatigue headache muscle ache pain injection site observed dose groups common increased vaccine low doses deemed safe effective order advance phase iii clinical trial using two doses administered days july moderna announced preliminary report operation warp speed candidate led production neutralizing antibodies healthy adults phase clinical dose one moderna advancing larger trials patients experienced side effects including fatigue chills headache muscle pain pain site troublesome higher doses discarded july future september study funded national institute allergy infectious diseases reported strong immune response six months even low doses suggesting doses could deployed limited vaccine supply six months lowdose vaccination participants still memory cytotoxic cells suggesting immune memory stable study also found crossreactive cells acquired infection coronaviruses cause common cold increased response moderna national institute allergy infectious diseases began phase iii trial us july plan enroll assign thirtythousand volunteers two groups one group receiving two doses vaccine receiving placebo sodium august volunteers enrolledcitation needed september moderna published detailed study plan clinical september ceo stéphane bancel said trial successful vaccine might available public early late march early april october moderna completed enrollment participants needed phase iii us national institutes health announced november overall trial results since september moderna used roche diagnostics elecsys test authorized us food drug administration fda emergency use authorization eua november according independent supplier clinical assays microbiology facilitate quantitative measurement antibodies help establish correlation vaccineinduced protection levels antireceptor binding domain rbd antibodies partnership announced roche december review fda december interim results phase iii clinical trial showed safe effective infection resulting issuance eua february results phase iii clinical trial published new england journal medicine indicating efficacy preventing side effects included flulike symptoms pain injection site fatigue muscle pain clinical trial ongoing set conclude late pregnant breastfeeding women also excluded initial trials used obtain emergency use though trials populations expected performed march order increase span vaccination beyond adults moderna started clinical trials vaccines children age us canada addition existing fullyenrolled study yearolds december moderna vaccine evaluation emergency authorization approval multiple countries would enable rapid rollout vaccine united kingdom european union eu canada united december moderna vaccine authorized us food drug administration fda emergency use authorization eua people aged years age first product moderna authorized june eua expanded include people aged six months sixteen years april authorization original monovalent version vaccine us april bivalent original omicron version vaccine authorized december moderna vaccine authorized health january moderna vaccine authorized use israel ministry february moderna vaccine authorized use singapore health sciences april world health organization granted emergency use may moderna vaccine authorized emergency use philippines philippines food drug moderna partnered takeda pharmaceutical company japan ministry health labour welfare vaccine known vaccine moderna intramuscular may vaccine moderna intramuscular injection formerly authorized emergency use june moderna vaccine authorized use india drugs controller general day vaccine also approved ministry health vietnam emergency use august malaysias national pharmaceutical regulatory agency npra gave conditional registration emergency use moderna january committee medicinal products human use chmp european medicines agency ema recommended granting conditional marketing recommendation accepted european commission july ema extended use vaccine moderna include people aged january swissmedic granted temporary authorization moderna mrna vaccine march medicines healthcare products regulatory agency mhra granted conditional marketing authorization united august spikevax granted provisional approval approval updated september include people aged twelve moderna spikevax vaccine authorized canada september people aged moderna spikevax vaccine authorized us january people aged moderna spikevax bivalent zeroomicron vaccine approved medical use united kingdom august september chmp ema recommended converting conditional marketing authorizations vaccine standard marketing recommendation covers existing upcoming adapted spikevax vaccines including recentlyapproved adapted spikevax bivalent originalomicron january moderna announced would offer third dose vaccine people vaccinated twice phase trial booster would made available participants six twelve months got second dose company said may also study third shot participants phase iii trial antibody persistence data warranted also started testing see third shot existing vaccine could used fend virus august us food drug administration fda us centers disease control prevention cdc authorized use additional mrna vaccine dose immunocompromised september committee medicinal products human use chmp european medicines agency ema started evaluating use booster dose moderna vaccine given least six months second dose people aged twelve years october european medicines agency ema stated people severely weakened immune systems receive extra dose either vaccine moderna vaccine starting least days second october us food drug administration fda centers disease control prevention cdc authorized use either homologous heterologous vaccine booster authorization expanded include adults november january moderna started development new form vaccine called could used booster shot beta variant lineage february moderna announced manufactured shipped sufficient amounts national institutes health run phase clinical moderna also investigated multivalent booster combines mix bivalent version vaccine containing elasomeranimelasomeran spikevax bivalent approved use united kingdom australia august approved use canada september october fda amended authorization bivalent booster cover people aged six years age december fda amended authorization bivalent booster cover people aged six months september fda approved updated monovalent single component omicron variant version vaccine spikevax formula single dose individuals aged twelve years age authorized moderna vaccine formula emergency use individuals aged months years updated version tested small human trial participants received monovalent version compared received version containing participants previously received four doses older formulations moderna vaccine safety profile authorized found consistent previously authorized approvals emergency authorizations bivalent version vaccine health canada authorized moderna spikevax vaccine omicron subvariant andusomeran september mhra approved use moderna spikevax vaccine september million doses moderna vaccine including million doses children adolescents years age administered eueea authorization june code name development elasomeran international nonproprietary name spikevax brand davesomeran inn variant bivalent version andusomeran inn xbb variant version june singapore signed prepurchase agreement moderna reportedly paying price premium order secure early stock vaccines although government declined provide actual price quantity citing commercial sensitivities confidentiality august us government signed agreement buy million doses modernas anticipated financial times said moderna planned price per november moderna said charge governments purchase vaccine per dose eu seeking price per dose million doses plans purchase moderna obtained purchase agreements european union million doses canada million december tweet belgium budget state secretary revealed eu would pay per dose new york times reported us would pay per moderna reported revenue million vaccine billion concern vaccine may increase risk myocarditis young people age finland sweden germany france recommended moderna vaccinations used age group octobernovember may releasing partial nonpeer reviewed results eight candidates preliminary prephase stage human trial directly financial markets ceo announced cnbc immediate billion rights issue raise funds company billion stat said vaccine experts say moderna didnt produce data critical assessing july disputes moderna government scientists companys unwillingness share data clinical trials moderna also faced criticism failing recruit people color clinical august us department health human services announced plan offer booster dose eight months second dose citing evidence reduced protection mild moderate disease possibility reduced protection severe disease hospitalization scientists reaffirmed lack evidence need booster dose healthy people vaccine remains effective severe disease months statement sage said protection infection may diminished protection severe disease likely retained due cellmediated research optimal timing boosters still ongoing booster early may lead less robust videos videosharing platforms circulated around may showing people magnets stick arms receiving vaccine purportedly demonstrating conspiracy theory vaccines contain microchips videos november white house correspondent conservative outlet newsmax falsely tweeted moderna vaccine contained luciferase pegylated lipid nanoparticle lnp drug delivery system subject ongoing patent litigation arbutus biopharma moderna previously licensed lnp september nature biotechnology reported moderna lost key challenge ongoing